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Abstract 
The use of laboratory procedures is often inefficient for materialisation of 
recombinant therapeutic proteins in Escherichia coli (E. coli) for pre-clinical 
evaluation. Approaches such as scaling out shake flask cultivation can be laborious, 
inefficient and expensive. These inefficiencies can be compounded if the protein 
requires post-translational modification such as multimerisation. We previously used 
laboratory methods to produce the <60kDa, recombinant biotherapeutic, RB1. We 
were aware, a priori, that dimeristion of RB1 could double the molecular weight of 
the protein and increase its systemic retention in the human body by avoiding renal 
filtration. Here we modified RB1 by substituting a native residue for an unpaired 
cysteine, generating eRB1, in order to favour its dimerisation. Laboratory methods 
failed to achieve >20% disulphide-bridged homodimerisation or monomer of 
sufficient purity to enable chemi-dimerisation. As such we established a set of high 
performance, bench-scale, unit operations for cultivation of E. coli cells expressing 
eRB1, the isolation of eRB1 inclusion bodies, refolding and disulphide-based 
dimerisation of ≥40% of total eRB1 and finally successful chemi-dimerisation of 
remaining monomeric eRB1. The establishment of scalable procedures can now 
enable future investigations of eRB1 and other <60kDa biologics for which significant 
bench-scale production is required for pre-clinical evaluation. 
 
Keywords Escherichia coli, inclusion body refolding, thiol engineering, recombinant 
biotherapeutic 
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1. Introduction 
We previously investigated a recombinant biotherapeutic protein, RB1, which posed 
challenges characteristic of early-stage biologics development i.e. the need for high-
performance but still relatively small-scale production and for protein engineering 
steps to increase efficacy. In this study we propose and test a bench-scale process 
for RB1 production that offers a high level of performance, is scalable and in a rapid 
and efficient manner provides sufficient material for efficacy evaluation. We 
demonstrate the process using a variant of RB1 that has undergone protein-
engineering to yield eRB1 in order to address the possibility of low systemic 
retention. We suggest the principle value in thie work is in mapping out a process for 
production and isolation of dimerised therapeutics at bench scale that is also 
scalable. We hope to provide a useful production starting point for researchers 
wishing to dimerise a given therapeutic protein for reasons of efficacy in addition to 
the goal of producing sufficient material for pre-clinical investigation. 
Our previous investigation of RB1 showed that it forms homoaggregate inclusion 
bodies (IBs) when expressed in the E. coli cytosol. IB formation can be desirable for 
high performance production of biologics, due to the high degree of purity of the 
constituent monomers (1), resistance to proteolysis (2) and ease of isolation from 
other E. coli host cell material (3). However developing such steps is often a 
challenge in a research setting geared toward clinical investigation as opposed to 
product materialisation. As such we were eager in this study to establish a set of 
procedures for addressing IB production that ideally were compatible with both 
bench scale equipment and any future pilot-scale unit operations. These steps would 
enable isolation of IBs then solubilisation and refolding of recombinant protein in a 
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way that is rapid and yields a sufficient quantity of therapeutically active protein for 
efficacy studies. 
The efficacy of a given biologic is frequently determined by its ability to bind to a 
specific target. This target binding often must be robust to a wide range of 
microenvironments, levels of target expression, and genetic variation across patient 
populations (4,5). In this study our strategy was to construct a variant, eRB1, in 
which a residue was substituted for an unpaired cysteine able to form a disulphide 
bridge between monomers (6,7). This was based on the a priori prediction that such 
dimerisation would double the effective molecular weight (MW) of the protein to take 
it above the so-called ‘renal threshold’. Upon administration to patients, RB1 is 
predicted to have a high propensity to loss by excretion due to its having a molecular 
weight (MW) below the renal threshold. Proteins of MW less than 30-60 kDa are 
likely to be excreted rapidly from patients during glomerular filtration (14). This is 
often problematic for treating disease states with recombinant proteins, as 
therapeutic target sites are typically scarce. As such, the longer a biologic can be 
retained in the circulation the more likely are encounters with therapeutic targets. 
Successful dimerisation of eRB1 will in effect double its MW and take it above the 
renal threshold. We assembled DNA encoding eRB1 by site-directed mutagenesis of 
the RB1 open reading frame (ORF) and subcloning the resultant RB1 ORF into an E. 
coli expression plasmid.  
In their native state many proteins use multiple intramolecular disulphide bonds 
between cysteine residue thiol groups to stabilise tertiary structure. Disulphide bonds 
cannot form in the E. coli cytoplasm as it is a reducing environment in which 
glutaredoxin and thioredoxin pathways act to reduce any thiol bridges via oxidation 
(8) of reduced nicotinamide adenine dinucleotide phosphate (NADPH) to cationic 
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NADP+. As such, our strategy would require IB formation ideally to persist in the 
eRB1 variant and would involve dimerisation of eRB1 only after its isolation from IBs. 
We investigated approaches to catalyse disulphide bridge formation between eRB1 
monomers in vitro by testing refolding conditions that favour disulphide bond 
formation and shuffling. 
We were also keen to develop alternative linking chemistries that might render the 
dimer bond stable to in vivo encounters with reducing microenvironments. To do this 
we investigated chemical crosslinking of monomeric eRB1 using bis-
maleimidohexane (BMH) to form a thioether bridge. BMH is commonly used for 
crosslinking cysteine residues to form thioether bonds. Maleimides are preferred for 
this process due to their high reactivity in aqueous solution, specificity for thiol 
groups and reactivity at neutral pH (9). Maleimide crosslinking is now a well-
established bioprocess option for dimerisarion of many licensed biotherapeutics (10–
12), including Rentuximab vedotin and Trastuzumab emtansine, both of which are 
approved by the United States Food and Drug Administration (13). A scalable 
process for BMH-mediated crosslinking could significantly shorten the timescale for 
materialisation of dimerised therapeutic proteins of which eRB1 serves as an 
example. 
 
2. Materials and Methods 
2.1 Chemicals, enzymes, and materials 
All chemicals were purchased from Sigma (UK) and were of analytical grade unless 
stated otherwise. Enzymes were purchased from New England Biolabs (UK) unless 
stated otherwise. 
2.2 Construction of therapeutic eRB1 expression strain 
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The E. coli TOP10 strain (Invitrogen, Paisley, UK) was used for cloning steps and 
the BL21 DE3 pLysS strain (Stratagene, Linford Wood, UK) for eRB1 expression. 
The RB1 ORF, encoded by a plasmid based on a pET29a vector (Novagen, UK) 
backbone, was modified to encode a cysteine substitution by site directed 
mutagenesis performed using the QuikChange® Site-Directed Mutagenesis Kit 
(Agilent, UK) and following the manufacturer’s instructions. The mutation was 
achieved with a single base substitution that converted the wild type codon to a 
cysteine codon, resulting in the eRB1 ORF. The eRB-29a vector now encoding 
eRB1 was transformed into BL21 DE3 pLysS E. coli using standard molecular 
biology techniques to give the eRB-BL21 strain (15).  
2.3 High cell density E. coli cultivation 
7.5 L New Brunswick BioFlo 110 bioreactors, following a protocol described 
previously (16), were used to cultivate cells expressing eRB1. Harvested process 
stream was divided into 500 mL centrifuge tubes (Beckmann) and centrifuged at 
6000 x g for 20 minutes at 4°C before storage overnight at -20oC. 
2.4 Refolding and purification of eRB1 
After overnight storage at -20°C cells were resuspended to 20% w/v solids in 50 mM 
Tris/50 mM NaCl, pH 7.4 and subjected to 5 passes at 500 Bar in a Lab60 
homogenizer to release the intracellular product (APV Invensys, London, UK). The 
homogenate was then divided into Beckmann 500 mL centrifuge tubes, and the 
insoluble cell debris pelleted by centrifugation at 6000 x g for 1 hour at 4oC. The 
inclusion body fraction was purified using methods previously described (16) and 
solubilised in 8 M urea / 0.1 M Tris / 2 mM dithiothreitol (DTT) / 440 mM reduced 
glutathione (GSH) / 1 mM ethylenediaminetetraacetic (EDTA) pH 9.3. The protein 
concentration of this mixture was determined by Bradford Assay before being added 
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at a rate of 1 mL / minute to a refolding buffer of 0.1 M Tris/0.5 M L-Arginine/2 mM 
EDTA/1 mM GSSG pH 8.5, at 4oC using a Model EP-1 Econo Pump (Bio-Rad 
Laboratories Ltd., Hertfordshire, UK) with stirring at 200 RPM. The volume of 
refolding buffer was adjusted to ensure a final protein concentration of 100 µg/mL 
and the solution was left to stand for 72 hours for refolding to take place. The 
solution was then dialysed against 50 mM sodium acetate pH 5 buffer for 24 hours 
with two buffer changes before loading onto a HiTrap SP FF Cation Exchange 
Column (GE Healthcare Sciences, Buckinghamshire, UK) and elution with a gradient 
of 0-1 M NaCl. Size Exclusion chromatography was performed with a 500 mL Fast 
Flow Sepharose column (GE Healthcare Sciences). Fractions were analysed by non-
reducing sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) 
for the presence of monomeric and dimeric eRB1. 
2.5 Chemical Cross-linking 
SEC fractions of eRB1 confirmed by SDS PAGE to contain no dimer were pooled 
and diluted to 5 mg/mL. As a precaution to remove any residual dimer not visible by 
SDS PAGE we added 5 mM tris (2-carboxyethyl) phosphine (TCEP) to the solution 
for a 30 minute incubation. This incubation with reducing agent should convert the 
remaining dimer to monomer. The TCEP was then removed, by desalting with a 
PD10 column (GE Healthcare Sciences) and 10 µL of 5.5 mg/mL 
bismaleimidohexane (BMH), from Thermo Fisher Scientific, Rockford, USA, in 
dimethylsulfoxide (DMSO) was added per mL of protein solution. This corresponds 
to 1:2 molar ratio of protein:BMH. The mixture was incubated for 1 hour at room 
temperature, and then the reaction was quenched by desalting with a PD10 column. 
The crosslinked protein was then separated from monomer and other reactants by 
cation exchange chromatography. 
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2.6 Expression and isolation of inclusions bodies formed by eRB1 in E. coli. 
We sought to establish a high performance bench scale production and recovery 
strategy in which the host strain was cultivated to high cell density using chemically 
defined media and a bioreactor to grow cells to high density (16). A triton/urea-based 
washing protocol would be used to obtain purified inclusion bodies (17) and a final 
two-step chromatographic process used to separate and purify monomeric and 
dimeric eRB1 (Figure 2). 
E. coli strain BL21 DE3 pLysS was used as host for the expression of eRB1. A seed 
culture of 200 mL LB with 35 µg/mL kanamycin was inoculated with a glycerol stock 
and grown at 37°C, 250 RPM until OD600 = 1.0. This seed culture was then used as 
a 10% inoculum for a 400 mL defined media culture grown at 30°C, 200 RPM until 
OD600 = 5.0. This defined culture was used as inoculum for a 7.5 L New Brunswick 
BioFlo 110 bioreactor containing 3.6 L defined media, to provide a starting OD600 of 
0.5. This bioreactor culture was grown following the Matos et al. protocol (16), 
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at mid-exponential 
phase, OD600 = 56. 48 hours after initial inoculation (Figure 3) the entire process 
stream was transferred to 0.5 L centrifuge bottle for centrifugation at 6000 x g in a 
J2-M1 device (Beckman-Coulter, Fullerton, CA, USA) with a JA10 rotor. Supernatant 
was decanted from the resultant pellets which were then frozen by storage at -20oC 
overnight. Frozen cell pellets were resuspended to 20% w/v in homogenisation 
buffer (50 mM Tris-HCl, 50 mM NaCl, pH 7.4) and subjected to 5 passes at 500 Bar 
in a Lab 60 homogenizer (APV Invensys, London, UK) to achieve complete lysis. 
The crude extract was centrifuged for 1 hour at 6,000 x g, 4°C, and the IB pellet 
washed with urea and Triton X-100 containing buffers to give a purified pellet (17). 
2.7 One step refolding and dimerisation of eRB1 from inclusion bodies 
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Recombinant biotherapeutics are often highly disulphide-linked, and so require 
extensive refolding when expressed within cytosolic IBs in E. coli cells. Altering the 
reducing conditions within the cytosol through gene knock outs (23) and co-
expression of folding chaperones (24, 25) has been shown to allow the recovery of 
active, correctly folded disulphide bonded proteins. Targeting recombinant 
therapeutic proteins to the oxidative periplasm has also successfully yielded active 
protein. However, IB-based refolding methods can enable a high yield of pure protein 
to be obtained due to the ease of separation from other cellular debris, the 
resistance of the IB to proteolysis, and the high yield obtainable due to the cytosolic 
compartment forming the majority of the volume of an E. coli cell (26). 
In this procedure the IB pellet was resuspended in solubilisation buffer (8 M Urea/0.1 
M Tris/2 mM DTT/440 mM GSH/1 mM EDTA pH 9.3). SDS-PAGE (Figure 4) was 
then used to estimate eRB1 yield and the protein solution was then added drop-wise 
to a pH 8.5 refolding buffer of 0.1 M Tris-HCl/0.5 M L-Arginine/2 mM EDTA/1 mM 
oxidised glutathione (GSSG) and incubated at 200 RPM, 4°C for 72 hours.  
 
3. Results and Discussion 
3.1 Thiol engineering of the novel recombinant biotherapeutic eRB1. 
Thiol groups and the disulphide bonding they direct are known to be key 
determinants of the biological function (18) and malfunction (19) of human proteins. 
Thiol engineering has previously been shown by others to facilitate the anchorage of 
protein units onto polymer capsules (20) and other immobilisation matrices (21). We 
also previously used protein engineering for removal of unpaired cysteine residues to 
reverse disulphide-driven multimerisation (22). 
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RB1 is a multidomain soluble protein with an even number of cysteine residues all of 
which are understood to form intramolecular disulphide bonds (Figure 1). The codon 
for a residue lying within an exposed loop of RB1 was converted to a cysteine codon 
using site directed mutagenesis to effect a single base pair substitution. The 
mutation was confirmed by sequencing and the engineered RB1 (eRB11) ORF was 
subcloned into pET29a in frame with a carboxy terminal hexahistidine tag to simplify 
purification.  
3.2 Purification of eRB1 
Poor results were observed with nickel affinity chromatography (data not shown) so 
a two-step purification procedure was developed using cation exchange followed by 
size exclusion chromatography. Cation exchange (CEX) was operated as a 
bind/elute process to remove impurities that had carried over from the previous stage 
and concentrate the protein solution down from 1-2L refolding buffer to 10-20mL total 
in elution buffer. For CEX, the refolded protein solution was dialysed into binding 
buffer (50 mM sodium acetate, pH 5.0), loaded onto a pre-equilibrated HiTrap SP FF 
Cation Exchange (GE Healthcare Sciences) column and eluted with a linear gradient 
of 0-1 M NaCl at a flow rate of 1 mL/min (Figure 5A). The fractions containing eRB1 
in monomeric and dimeric forms (Figure 5B) were then pooled, dialysed into 
Dulbecco’s phosphate buffered saline, concentrated to a volume of 5 mL and then 
separated on a Superdex 500 Size Exclusion Chromatography (GE Healthcare 
Sciences) column (Figure 6A). Purity of the eluted fractions was estimated at 95% by 
SDS-PAGE analysis (Figure 6B) and the yield of purified protein determined by 
absorbance at 280 nM (Table 1). In total, 108 mg of purified eRB1 was obtained, 
which correlates to a yield from fermentation of 27 mg/L. This was divided 
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approximately 50:50 between monomer and dimer forms. The monomer fraction was 
then pooled to use for further chemical crosslinking.  
3.3 Chemi-dimerisation of remaining eRB1 monomer 
Monomeric fractions from the size exclusion chromatography were pooled and 
reduced by incubation with tris(2-carboxyethyl)phosphine (TCEP) to remove any co-
eluted dimer then chemically crosslinked with BMH to form a thioether-bridged 
dimer. Once the crosslinking reaction was complete, cation exchange 
chromatography was used to separate eRB1 from reactants (Figure 7A). Thioether 
bonds are far more resistant to reduction-based scission than disulphide bridges. As 
such the persistence of dimer bands during reducing SDS-PAGE is evidence of 
thioether-based eRB1 dimerisation (Figure 7B). 
 
4. Conclusions 
We were motivated to establish a high performance process for timely 
materialisation of the relatively low MW (<60kDa) biotherapeutic eRB1 for extensive 
pre-clinical characterisation. We intended that scaling up of each step will be 
straightforward and the process should be applicable to a range of different 
biotherapeutics that possess similar amino acid sequence properties as those of 
eRB1, depicted in Figure 1. 
Figure 2 sets out our proposed 14-step production process with which we achieved 
greater than 95% purity in the final product. All steps of the process were scalable 
but the final SEC step is relatively slow so would need to be replaced with 
approaches such as anion exchange or hydrophobic interaction chromatography in 
order to achieve levels of purity mandated by regulators within acceptable 
timescales. 
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We successfully dimerised RB1 by point mutation to bring about a single amino acid 
substitution, generating eRB1, then subjecting the protein to oxidising conditions 
during an IB refolding step. We were also able to convert any remaining undimerised 
eRB1 protein to homodimers by thioether bridging of thiol groups, a method that has 
been applied to a variety of recombinant protein therapeutics, such as IgG1 
monoclonal antibodies (27), somatostatin (28) and other complex heterodimers (29). 
Previously, when using laboratory methods to materialise RB1 variants we achieved 
≤20% disulphide-bridged homodimerisation and the remaining monomer was of 
insufficient purity for successful chemi-dimerisation. 
In conclusion, we present a largely scalable bench process for production of a 
homodimeric biotherapeutic protein that achieves high levels of performance with 
respect to the level of disulphide-based dimerisation (≥40%) and the level of purity, 
which is sufficient to enable chemi-dimerisation of remaining monomer. We 
anticipate this work will inform future laboratory-scale pre-clinical investigation of 
putative biotherapeutics of comparable MW and sequence. 
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Figures 
Figure 1. Schematic of therapeutic recombinant protein RB1. Hopps-Woods 
hydropathy analysis and sequence characteristics of RB1, hydrophilic residues are 
shown above central line, hydrophobic below. 
Figure 2. High performenace bench scale process for eRB1 production. A) 
Process flow sheet of eRB1 production and isolation. B) Process diagram for which 
the process flow sheet provides a key. 
Figure 3. Growth profile of E. coli cells harbouring eRB1 expression plasmid.  
Cell growth performance in a 7.5 L bioreactor. IPTG was added to 1mM 
concentration at OD600 = 56 to induce eRB1 expression. Data is representative of 
n=3 biological repeats. 
Figure 4. eRB1 IB isolation. SDS PAGE analysis of inclusion body washing 
strategy. Lane 1: resuspended insoluble fraction post homogenisation (step 5 in 
Figure 2). Lane 2: purified inclusion body fraction post washing; Lane 3: purified RB1 
monomer as marker. 
Figure 5. Isolation of refolded eRB1. (A) Cation exchange chromatography of 
refolded eRB. Samples were eluted with a linear gradient of 0-1 M NaCl and a flow 
rate of 1 mL/min. (B) A selection of 1 mL fractions (fraction number indicated above 
lanes) were taken and analysed by non-reducing SDS PAGE to visualised monomer 
and dimer forms of eRB1. Red arrow indicates dimer. Purifided, monomeric RB1 was 
run in lane labelled ‘RB1’ for comaprison. 
Figure 6. Purification of eRB1 monomer and dimer solutions. (A) Size exclusion 
chromatography of eRB1 containing fractions containing predominantly dimer or 
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monomer. (B) 5 mL fractions analysed by non-reducing SDS-PAGE to visualise 
monomer (lanes 240, 250 and 260) and dimer (lanes 270, 280 and 290). Black 
triangle indicates dimer MW, grey triangle indicates monomer MW. 
 
Figure 7. Chemi-dimerisation of remaining eRB1 monomer. Crosslinking of 
eRB1 monomers with BMH renders them resistant to dimer-bond scission by 
reducing conditions. (A) Cation exchange chromatography was used to separate 
eRB1 from BMH reactants. (B) Photographs of reducing SDS PAGE performed on 
samples that contained disulphide-linked eRB1 dimers (eRB1 -SS-) and eRB1 
monomer treated with BMH to drive thiother-linked dimerisation (eRB1 -S-). Black 
triangle indicates dimer MW, grey triangle indicates monomer MW. 
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Purification stage Total protein (mg) Purity of eRB1(%) Dimer Percentage 
(%) 
Insoluble fraction ND <10 ND 
Washed inclusion 
bodies 
211 80 NA 
Cation exchange 
peaks 
151 90 40 
Size Exclusion 
fractions 271-300 
53.2 >95 >95 
Table 1 Protein concentration and purity obtained at different points in recovery. 
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